47.83
0.10%
-0.05
Vericel Corp stock is currently priced at $47.83, with a 24-hour trading volume of 342.89K.
It has seen a -0.10% decreased in the last 24 hours and a -6.82% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $47.71 pivot point. If it approaches the $48.41 resistance level, significant changes may occur.
Previous Close:
$47.88
Open:
$48.87
24h Volume:
342.89K
Market Cap:
$2.31B
Revenue:
$197.52M
Net Income/Loss:
$-3.18M
P/E Ratio:
-164.93
EPS:
-0.29
Net Cash Flow:
$7.80M
1W Performance:
+3.87%
1M Performance:
-6.82%
6M Performance:
+29.76%
1Y Performance:
+48.91%
Vericel Corp Stock (VCEL) Company Profile
Name
Vericel Corp
Sector
Industry
Phone
617-588-5555
Address
64 Sidney Street, Cambridge, MA
Vericel Corp Stock (VCEL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-25-24 | Upgrade | Truist | Hold → Buy |
Aug-08-23 | Upgrade | BTIG Research | Neutral → Buy |
Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
Nov-09-22 | Downgrade | Truist | Buy → Hold |
Oct-14-22 | Resumed | Stephens | Overweight |
Jan-11-21 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-18-20 | Initiated | Stephens | Overweight |
Sep-17-20 | Initiated | Truist | Buy |
Oct-09-19 | Initiated | H.C. Wainwright | Buy |
Feb-28-19 | Downgrade | Needham | Buy → Hold |
Aug-08-18 | Reiterated | Needham | Buy |
Jul-16-18 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Apr-04-18 | Initiated | Leerink Partners | Outperform |
Mar-06-18 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Mar-06-18 | Reiterated | Needham | Buy |
Mar-05-18 | Reiterated | BTIG Research | Buy |
Jun-21-17 | Initiated | BTIG Research | Buy |
Mar-13-17 | Reiterated | Needham | Buy |
Dec-22-16 | Initiated | Piper Jaffray | Overweight |
Nov-09-16 | Reiterated | Needham | Buy |
Apr-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
Mar-11-16 | Upgrade | Needham | Hold → Buy |
View All
Vericel Corp Stock (VCEL) Latest News
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
GlobeNewswire Inc.
Analyst Scoreboard: 5 Ratings For Vericel
Benzinga
A Closer Look at 4 Analyst Recommendations For Vericel
Benzinga
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Zacks Investment Research
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
GlobeNewswire Inc.
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Vericel Corp Stock (VCEL) Financials Data
Vericel Corp (VCEL) Revenue 2024
VCEL reported a revenue (TTM) of $197.52 million for the quarter ending December 31, 2023, a +20.17% rise year-over-year.
Vericel Corp (VCEL) Net Income 2024
VCEL net income (TTM) was -$3.18 million for the quarter ending December 31, 2023, a +80.96% increase year-over-year.
Vericel Corp (VCEL) Cash Flow 2024
VCEL recorded a free cash flow (TTM) of $7.80 million for the quarter ending December 31, 2023, a -22.72% decrease year-over-year.
Vericel Corp (VCEL) Earnings per Share 2024
VCEL earnings per share (TTM) was -$0.08 for the quarter ending December 31, 2023, a +77.78% growth year-over-year.
About Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):